Author: Mark Newman
A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and...
As pediatric diabetes cases continue to rise, a number of manufacturers have created products that make managing the disease a little less scary for these younger patients. Pediatric diabetes is on the rise. While type 1 diabetes can develop at any age, it is most prevalent in children and teens – the average age of...
Antidepressants May Improve Outcomes in People with Diabetes and Depression
People with diabetes and depression who take antidepressants may have a lower risk of death and of serious diabetes complications, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. People with diabetes face a higher risk of depression, which makes them more likely to die or develop diabetes complications...
Teamwork is often vital to improving patient outcomes. And while most healthcare professionals are in favor of working together, the biggest obstacle appears to be simply finding the time to team up. In a survey conducted last summer by the market research and analytics company The Harris Poll for Boehringer Ingelheim and Eli Lilly and...
Immerse Yourself in the Latest Advances at Our Fall Meetings